All News #Library
Rare Diseases
Hansa Updates Pivotal Phase 3 Anti-GBM Disease Trial
17 Dec 2025 //
PHARMIWEB
Hansa Bio data at 2025 PNS Meeting shows imlifidase potential
14 May 2025 //
PR NEWSWIRE
Hansa Bio`s Positive Results from Ph 2 in Guillain-Barré Syndrome
17 Dec 2024 //
PR NEWSWIRE
Genethon, Hansa Begin Phase 2 for Imlifidase in Crigler-Najjar
03 Dec 2024 //
PR NEWSWIRE

Market Place
Sourcing Support